Literature DB >> 29925692

Double-stranded RNA innate immune response activation from long-term adeno-associated virus vector transduction.

Wenwei Shao1, Lauriel F Earley1, Zheng Chai1, Xiaojing Chen1, Junjiang Sun1,2, Ting He1, Meng Deng3, Matthew L Hirsch1,4, Jenny Ting3, R Jude Samulski1,5, Chengwen Li1,6,7.   

Abstract

Data from clinical trials for hemophilia B using adeno-associated virus (AAV) vectors have demonstrated decreased transgenic coagulation factor IX (hFIX) expression 6-10 weeks after administration of a high vector dose. While it is likely that capsid-specific cytotoxic T lymphocytes eliminate vector-transduced hepatocytes, thereby resulting in decreased hFIX, this observation is not intuitively consistent with restored hFIX levels following prednisone application. Although the innate immune response is immediately activated following AAV vector infection via TLR pathways, no studies exist regarding the role of the innate immune response at later time points after AAV vector transduction. Herein, activation of the innate immune response in cell lines, primary human hepatocytes, and hepatocytes in a human chimeric mouse model was observed at later time points following AAV vector transduction. Mechanistic analysis demonstrated that the double-stranded RNA (dsRNA) sensor MDA5 was necessary for innate immune response activation and that transient knockdown of MDA5, or MAVS, decreased IFN-β expression while increasing transgene production in AAV-transduced cells. These results both highlight the role of the dsRNA-triggered innate immune response in therapeutic transgene expression at later time points following AAV transduction and facilitate the execution of effective strategies to block the dsRNA innate immune response in future clinical trials.

Entities:  

Keywords:  Gene therapy; Immunology; Innate immunity; Therapeutics

Mesh:

Substances:

Year:  2018        PMID: 29925692      PMCID: PMC6124417          DOI: 10.1172/jci.insight.120474

Source DB:  PubMed          Journal:  JCI Insight        ISSN: 2379-3708


  48 in total

1.  IL-28, IL-29 and their class II cytokine receptor IL-28R.

Authors:  Paul Sheppard; Wayne Kindsvogel; Wenfeng Xu; Katherine Henderson; Stacy Schlutsmeyer; Theodore E Whitmore; Rolf Kuestner; Ursula Garrigues; Carl Birks; Jenny Roraback; Craig Ostrander; Dennis Dong; Jinu Shin; Scott Presnell; Brian Fox; Betty Haldeman; Emily Cooper; David Taft; Teresa Gilbert; Francis J Grant; Monica Tackett; William Krivan; Gary McKnight; Chris Clegg; Don Foster; Kevin M Klucher
Journal:  Nat Immunol       Date:  2002-12-02       Impact factor: 25.606

Review 2.  Innate immune pattern recognition: a cell biological perspective.

Authors:  Sky W Brubaker; Kevin S Bonham; Ivan Zanoni; Jonathan C Kagan
Journal:  Annu Rev Immunol       Date:  2015-01-02       Impact factor: 28.527

3.  Differential activation of innate immune responses by adenovirus and adeno-associated virus vectors.

Authors:  Anne-Kathrin Zaiss; Qiang Liu; Gloria P Bowen; Norman C W Wong; Jeffrey S Bartlett; Daniel A Muruve
Journal:  J Virol       Date:  2002-05       Impact factor: 5.103

4.  Long-term safety and efficacy following systemic administration of a self-complementary AAV vector encoding human FIX pseudotyped with serotype 5 and 8 capsid proteins.

Authors:  Amit C Nathwani; Cecilia Rosales; Jenny McIntosh; Ghasem Rastegarlari; Devhrut Nathwani; Deepak Raj; Sushmita Nawathe; Simon N Waddington; Roderick Bronson; Scott Jackson; Robert E Donahue; Katherine A High; Federico Mingozzi; Catherine Y C Ng; Junfang Zhou; Yunyu Spence; M Beth McCarville; Marc Valentine; James Allay; John Coleman; Susan Sleep; John T Gray; Arthur W Nienhuis; Andrew M Davidoff
Journal:  Mol Ther       Date:  2011-01-18       Impact factor: 11.454

5.  Safe and efficient transduction of the liver after peripheral vein infusion of self-complementary AAV vector results in stable therapeutic expression of human FIX in nonhuman primates.

Authors:  Amit C Nathwani; John T Gray; Jenny McIntosh; Catherine Y C Ng; Junfang Zhou; Yunyu Spence; Melanie Cochrane; Elaine Gray; Edward G D Tuddenham; Andrew M Davidoff
Journal:  Blood       Date:  2006-11-07       Impact factor: 22.113

Review 6.  Interferon-stimulated genes and their antiviral effector functions.

Authors:  John W Schoggins; Charles M Rice
Journal:  Curr Opin Virol       Date:  2011-12       Impact factor: 7.090

Review 7.  RIG-I in RNA virus recognition.

Authors:  Alison M Kell; Michael Gale
Journal:  Virology       Date:  2015-03-05       Impact factor: 3.616

Review 8.  To translate, or not to translate: viral and host mRNA regulation by interferon-stimulated genes.

Authors:  Melody M H Li; Margaret R MacDonald; Charles M Rice
Journal:  Trends Cell Biol       Date:  2015-03-03       Impact factor: 20.808

9.  Activation of nucleotide oligomerization domain 2 (NOD2) by human cytomegalovirus initiates innate immune responses and restricts virus replication.

Authors:  Arun Kapoor; Michael Forman; Ravit Arav-Boger
Journal:  PLoS One       Date:  2014-03-26       Impact factor: 3.240

Review 10.  Pattern Recognition and Signaling Mechanisms of RIG-I and MDA5.

Authors:  Stephanie Reikine; Jennifer B Nguyen; Yorgo Modis
Journal:  Front Immunol       Date:  2014-07-23       Impact factor: 7.561

View more
  29 in total

1.  AAV Immunogenicity: New Answers Create New Questions.

Authors:  Jamie L Shirley; Roland W Herzog
Journal:  Mol Ther       Date:  2018-10-23       Impact factor: 11.454

2.  BAX 335 hemophilia B gene therapy clinical trial results: potential impact of CpG sequences on gene expression.

Authors:  Barbara A Konkle; Christopher E Walsh; Miguel A Escobar; Neil C Josephson; Guy Young; Annette von Drygalski; Scott W J McPhee; R Jude Samulski; Ivan Bilic; Maurus de la Rosa; Birgit M Reipert; Hanspeter Rottensteiner; Friedrich Scheiflinger; John C Chapin; Bruce Ewenstein; Paul E Monahan
Journal:  Blood       Date:  2021-02-11       Impact factor: 22.113

3.  Adeno-Associated Virus Serotype-Specific Inverted Terminal Repeat Sequence Role in Vector Transgene Expression.

Authors:  Lauriel F Earley; Laura M Conatser; Victoria M Lue; Amanda L Dobbins; Chengwen Li; Matthew L Hirsch; R Jude Samulski
Journal:  Hum Gene Ther       Date:  2020-02       Impact factor: 5.695

4.  Inherent hepatocytic heterogeneity determines expression and retention of edited F9 alleles post-AAV/CRISPR infusion.

Authors:  Qiang Wang; Lin Zhang; Guo-Wei Zhang; Jian-Hua Mao; Xiao-Dong Xi; Lu Jiang; Gang Lv; Jing Lu; Yan Shen; Zhu Chen; Jiang Zhu; Sai-Juan Chen
Journal:  Proc Natl Acad Sci U S A       Date:  2021-10-19       Impact factor: 11.205

Review 5.  AAV Vector Immunogenicity in Humans: A Long Journey to Successful Gene Transfer.

Authors:  Helena Costa Verdera; Klaudia Kuranda; Federico Mingozzi
Journal:  Mol Ther       Date:  2020-01-10       Impact factor: 11.454

Review 6.  Adeno-associated viral vector-mediated immune responses: Understanding barriers to gene delivery.

Authors:  Natalie F Nidetz; Michael C McGee; Longping V Tse; Chengwen Li; Le Cong; Yunxing Li; Weishan Huang
Journal:  Pharmacol Ther       Date:  2019-12-11       Impact factor: 12.310

7.  Challenges Posed by Immune Responses to AAV Vectors: Addressing Root Causes.

Authors:  Bradley A Hamilton; J Fraser Wright
Journal:  Front Immunol       Date:  2021-05-17       Impact factor: 7.561

8.  Ocular Inflammation and Treatment Emergent Adverse Events in Retinal Gene Therapy.

Authors:  Neesurg Mehta; Deborah A Robbins; Glenn Yiu
Journal:  Int Ophthalmol Clin       Date:  2021-07-01

9.  Membrane fusion FerA domains enhance adeno-associated virus vector transduction.

Authors:  Xintao Zhang; Bui Anthony; Zheng Chai; Amanda Lee Dobbins; Roger Bryan Sutton; Chengwen Li
Journal:  Biomaterials       Date:  2020-02-21       Impact factor: 12.479

Review 10.  Overcoming innate immune barriers that impede AAV gene therapy vectors.

Authors:  Manish Muhuri; Yukiko Maeda; Hong Ma; Sanjay Ram; Katherine A Fitzgerald; Phillip Wl Tai; Guangping Gao
Journal:  J Clin Invest       Date:  2021-01-04       Impact factor: 14.808

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.